definiens: shall mean [COMPANY] 's OncoCEE - LUTM ( and OncoCEE - LUTM with Mutation Analysis ) laboratory developed assay for characterization and profiling of CTCs from NSCLC patients, which shall incorporate, as Phase 1, CTC enumeration by cytokeratin and CD45 ( mId CEE - Enhanced ™ when available ), EML4 / Alkl fusions and EGFR amplification by fluorescence in situ hybridization ( determined by [COMPANY] ) ; and as Phase 2, the additional detection of mutations for relevant e.g., K - RAS, EGFR and B - RAF, as by the parties, on captured CTCs and/or cell - free circulating DNA, as agreed by the parties, and employing technologies that potentially may include [COMPANY] 's Selector technology, and any improvements or enhancements thereto, exclusive of new analyies ( which are discussed in Section 3.5(f ) under Collaboration Assays ) or applications to primary screening . 1.3 shall mean [COMPANY], Inc., '' OncoCEE - LU ™,,,, '' CEE - Sure ™,,, CEE - Enhanced ™ '', and/or such other trademarks and trade names owned or licensed, and used, by [COMPANY] and/or its Affiliates in the Ten : itory to identify the Tests, in each case, whether or not registered